✦ LIBER ✦

Anastrozole (‘Arimidex’) blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer

✍ Scribed by Miller, W R; Stuart, M; Sahmoud, T; Dixon, J M

Book ID: 109997389
Publisher: Nature Publishing Group
Year: 2002
Tongue: English
Weight: 121 KB
Volume: 87
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6600587

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of anastrozole versus tamoxif

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer : The pre-operative “Arimidex” compared to Tamoxifen (PROACT) trial

✍ Luigi Cataliotti; Aman U. Buzdar; Shinzaburo Noguchi; Jose Bines; Yuichi Takatsu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

## Abstract ## BACKGROUND The Pre‐Operative “Arimidex” Compared to Tamoxifen (PROACT) study was a randomized, multicenter study comparing anastrozole with tamoxifen as a preoperative treatment of postmenopausal women with large, operable (T2/3, N0‐2, M0), or potentially operable (T4b, N0‐2, M0) br

Peripheral oestrogen metabolism in postm

Peripheral oestrogen metabolism in postmenopausal women with or without breast cancer: The role of dietary lipids and growth factors

✍ M.J. Reed; P.A. Beranek; R.W. Cheng; J.M. McNeill; V.H.T. James 📂 Article 📅 1987 🏛 Elsevier Science 🌐 English ⚖ 578 KB

Anastrozole (‘Arimidex’) versus tamoxife

Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial

✍ Beat Thürlimann; Dagmar Hess; Dieter Köberle; Isabella Senn; Pierluigi Ballabeni 📂 Article 📅 2004 🏛 Springer US 🌐 English ⚖ 348 KB

Anastrozole is safer and may be more eff

Anastrozole is safer and may be more effective than tamoxifen in postmenopausal women with early-stage breast cancer: Abstracted from: Baum M, Buzdar A, Cuzick J, et al. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Cancer 2003;98:1802–10

✍ Hetty Carraway; Antonio C. Wolff 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 151 KB

Preliminary results of a large comparati

Preliminary results of a large comparative multi-centre clinical trial comparing the efficacy and tolerability of Armidex™ (Anastrozole) and Tamoxifen (TAM) in postmenopausal women with advanced breast cancer (ABC)

✍ Bonneterre, J.; Thürlimann, B.J.K.; Robertson, J.F.R. 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 132 KB

Anastrozole alone or in combination with

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer : Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses

✍ The ATAC (Arimidex; Tamoxifen Alone or in Combination) Trialists' Group 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 2 views

## Abstract ## BACKGROUND The first analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial (median follow‐up, 33 months) demonstrated that in adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer, anastrozole was superior to tamoxifen in terms of d